ScienceModerna and Merck unveil mRNA cancer vaccine that cuts melanoma spread

Moderna and Merck say their personalised mRNA vaccine Intismeran reduced melanoma recurrence and tumour spread in a late-stage trial. Full results are pending, while the companies are discussing the treatment with regulators; Moderna’s shares briefly jumped 160 percent after the announcement.

mRNA vaccinecancer treatmentmelanomaModerna

AAl Jazeera★★★★☆2026-08-19 20:39Original